OneOncology Finalizes 25 Clinical Pathways in Oncology and Hematology

OneOncology has completed 25 unique oncology and hematology pathways, and all have been published inside the platform’s clinical decision support tool, according to a news release from OneOncology.

Leaders in developing the pathways included experts from OneOncology’s 5 disease groups (gastrointestinal, genitourinary, breast, lung, and hematology) and disease subject matter experts (gynecology, head, and neck), according to Edward Arrowsmith, MD, medical director of OneOncology’s Pathways Program.

These proprietary pathways “are concordant with many nationally recognized evidence-based guidelines and are reviewed and updated regularly” after data are presented at national or international meetings, such as the American Society of Clinical Oncology Annual Meeting, or when major papers are published in peer-reviewed journals, the news release noted.

According to OneOncology, pathways are delineated by stage and treatment options for each stage, including neoadjuvant, adjuvant, recurrent, locally advanced, and metastatic treatment settings.

“Our cancer patient population is very diverse, and pathways must account for the numerous clinical scenarios that can present in each cancer type,” Davey Daniel, MD, OneOncology’s chief medical officer, said. “OneOncology’s pathways list various treatment options, ensuring they are all-encompassing and include when clinical trials are available for a specific cancer setting. The goal of OneOncology’s Pathways Program is to streamline the ordering process for physicians and efficiently put the latest medical evidence into the hands of all of our physician partners.”

As explained in the news release, the process works as follows:

• Pathway development begins with the Pharmacy and Therapeutics (P&T) Committee, which reviews and approves all new indications or new molecular entities. The P&T Committee is an entity of the all-physician body called OneCouncil, led by OneOncology partner physicians.
• A drug monograph is authored, which must be approved by the P&T Committee.
• The approved agent monograph is incorporated in draft form into the appropriate pathway and presented to the appropriate OneCouncil Disease Group.
• Disease Group members decide if and where an agent should be added to the pathway. Members weigh the merits of the new agent or indication based on its efficacy and adverse event profile, relative to other treatment options

“Efficacy and safety are the first priorities of our Pathways Program,” said Lisa Raff, PharmD, MSPharm, BCPS, BCOP, OneOncology’s vice president of pharmacy services. “[Although] we consider contracting and cost factors within a drug class to identify treatment regimens that can provide cost savings for patients, it occurs after a clinical pathway has been approved. Overall, the goal of our pathways is to increase appropriate first-line treatment based on genomic testing and biomarkers and participation in value-based care programs, while reducing adverse events experienced by patients due to standardized regimens and appropriate supportive care.” 

Reference
Hoffman E. OneOncology finalizes 25 oncology and hematology pathways. OneOncology. August 28, 2023. Accessed September 21, 2023. https://bit.ly/3PKxSkD